Clinitech Laboratory Limited (BSE SME)
July 25, 2024 – July 29, 2024
| Price | ₹96 - ₹96 |
| Premium | ₹65 |
|---|---|
| Lot size | 1200 |
| Allotment | Jul 30, 2024 |
| Listing | Aug 1, 2024 |
Clinitech Laboratory Limited
AL-1/545, Sector 16, Airoli
Opposite Radhikabai Meghe Vidyalaya
Navi Mumbai, Thane - 400708,
Phone: +91 22 27792281
Email: ipo@clinitechlab.com
Website: https://clinitechlab.com/
Last updated on 29-Jul-2024 15:42:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| HNIs | 285600 | 6390000 | 22.37 |
| Retail | 285600 | 13275600 | 46.48 |
| Total | 571200 | 19665600 | 34.43 |
| Total Applications: 15973 | |||
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹2.88 | @8% ₹3.29 | @9% ₹3.71 | @10% ₹4.12 | @11% ₹4.53 | @12% ₹4.94 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 1200 | 115200 | 238 |
| HNI | 2 | 2400 | 230400 | 238 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 47.4% | 285600 |
| Other | 47.4% | 285600 |
| Market Maker | 5.18% | 31200 |
| Total No. of Shares | 100.0% | 602400 |
Clinitech Laboratory IPO Details
| Issue Size | 602,400 shares (aggregating up to ₹5.78 Cr) |
| Fresh Issue | 602,400 shares (aggregating up to ₹5.78 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE SME |
| Share holding pre issue | 1,680,000 |
| Share holding post issue | 2,282,400 |
| Market Maker portion | 31,200 shares Bhh Securities |
Key Performance Indicator
| KPI | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|
| RONW | 10.46% | 25.75% | 27.74% |
| D/E | 0.24 | 0.41 | 0.47 |
| EPS (basic) | 2.37 | 4.09 | 3.42 |
| P/E Pre IPO | 43.45 | ||
| P/E Post IPO | 59.03 |
Company Financials
Clinitech Laboratory Limited Financial Information (Restated)
Clinitech Laboratory Limited's revenue decreased by -1.45% and profit after tax (PAT) rose by 19.61% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Assets | 560.79 | 603.33 | 368.74 | 273.32 |
| Revenue | 643.92 | 636.34 | 645.70 | 459.63 |
| Profit | 37.12 | 61.31 | 51.26 | 40.24 |
| Net Worth | 354.80 | 238.08 | 184.81 | 139.03 |
| Reserves | 186.80 | 88.08 | 34.81 | 72.37 |
| Borrowing | 86.31 | 102.91 | 88.61 | 53.67 |
| Amount in ₹ Lakhs | ||||
About Section
Founded in 1990, Clinitech Laboratory Limited operates 8 diagnostic centers in and around Thane and Navi Mumbai, providing a wide range of diagnostic and healthcare tests and services. The company conducts over 300,000 tests annually in its NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs, which are equipped with state-of-the-art technology and high-end equipment. The medical testing facility in Airoli, Navi Mumbai, has been awarded a Certificate of Accreditation by NABL in accordance with ISO 15189:2012. As of December 31, 2023, Clinitech Laboratory Limited employs 74 people across various departments, ensuring efficient and reliable healthcare services.
Strength
NABL Accreditation: Clinitech Laboratory Limited's labs are accredited by the National Accreditation Board for Testing and Calibration Laboratories, ensuring high standards and reliability in diagnostics.
Chain of Diagnostic Centers: The company operates 8 well-equipped diagnostic centers in Thane and Navi Mumbai, offering extensive diagnostic and healthcare services.
Experienced Leadership: The company benefits from an experienced promoter and management team with strong industry expertise and a successful track record, driving its growth and reputation.
Weakness
Brand Maintenance: Failure to maintain and grow Clinitech Laboratory Limited's brand name and image could adversely affect its business prospects.
Quality Standards: Inability to consistently maintain high-quality standards may negatively impact the company's business, results of operations, and financial condition.
Geographic Concentration: The company's operations are concentrated in Thane and Navi Mumbai, making it vulnerable to regional disruptions that could adversely affect its business and financial health.